# Galantamine

Source: https://onco.cc/drugs/da-galantamine/  
OnCo record `da-galantamine` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Galantamine is a tablet for mild-to-moderate dementia of the Alzheimer’s type. It is not approved for vascular, frontotemporal, or Lewy body dementia.

## Summary

US labeling is specific to the Alzheimer’s type. Using it off-label for another subtype needs a clinician who has weighed limited benefit against harm.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-21
- Tags: dementia-atlas
- Brand: Razadyne
- Modality: small molecule
- Mechanism: Cholinesterase inhibitor.
- Approvals: US 2001: Mild-to-moderate dementia of the Alzheimer’s type; EU 2000: Alzheimer’s dementia; UK 2000: Alzheimer’s dementia; JP 2011: Alzheimer’s dementia; CN 2006: Alzheimer’s dementia; AU 2001: Alzheimer’s dementia

## Sources

- FDA label index: https://www.accessdata.fda.gov/scripts/cder/daf/

## Connected records

- diagnoses: [Alzheimer’s disease](https://onco.cc/diagnoses/alzheimers-disease/)
- targets: [Acetylcholinesterase](https://onco.cc/targets/da-target-ache/)
- technologies: [Cholinesterase inhibitors](https://onco.cc/technologies/da-tech-cholinesterase-inhibitors/)

---
JSON: https://onco.cc/api/v1/entities/da-galantamine.json